Oxford launches PharmaSense

Oxford Instruments has launched its PharmaSense product at this year’s Controlled Release Society (CRS) Meeting in New York.

The organisation claims the instrument is specifically designed to address the needs of the drug formulation community within the pharmaceutical industry.

Frank Trundle, managing director of Oxford’s molecular biotools division, said the firm is delighted to be ready to run customer samples and discuss delivery and pricing of the product.

"PharmaSense is an exciting new instrument. By combining MRI and a USP-4 compatible dissolution flow cell, it could help drug formulation chemists enhance tablet design, and so improve drug efficacy and patient compliance," he added.

Last month the firm announced booming first-quarter turnover for 2008 as its revenue reached £176.5 million – up by 9.2 per cent from the first three months last year.

Oxford claims to be the leading provider of tools and systems for the emerging nanotechnology and bioscience markets.

It specialises in the design, manufacture and support of high-technology tools and systems for industry, research, education, space, energy, defence and healthcare.